Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03947346 · ClinicalTrials.gov registry record
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 28
- Enrollment target
NCT03947346: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03947346 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03947346 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
Interventions
- OTHER Urine sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2025-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03947346
The ClinicalTrials.gov registry entry for NCT03947346 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Urine sample is the first listed.
NCT03947346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03947346 about?
NCT03947346 is a clinical study titled "Biomarkers of Renal Dysfunction in Neuroblastoma Survivors". The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or diseas...
What is the current status of trial NCT03947346?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-05-09. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT03947346?
The interventions under investigation include: Urine sample (OTHER).
Who is sponsoring clinical trial NCT03947346?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.